BEST UNLIMITED TURBO LONG CERTIFICATE - NOVO-NORDISK B | Market Closed - Euronext Paris 12:30:00 2024-07-15 pm EDT | ||
| 21.94 EUR | -0.07% |
|
| Current month | -3.89% | ||
| 1 month | -2.83% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-15 | 21.94 | -0.07% |
| 24-07-12 | 21.96 | +1.39% |
| 24-07-11 | 21.66 | -1.80% |
| 24-07-10 | 22.05 | +0.85% |
| 24-07-09 | 21.87 | -2.13% |
Real-time Euronext Paris
Last update July 15, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| CD06Z | |
| ISIN | DE000CJ3P4M8 |
| Date issued | 2018-11-09 |
| Strike | 156.9 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 0.25 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.82 € |
|---|---|
| Lowest since issue | 0.165 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
973.3
DKK
Average target price
956.5
DKK
Spread / Average Target
-1.72%
- Stock Market
- Certificates
- CD06Z Certificat
